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especially deletions, have been acknowledged [5] . CTCs, shed from solid tumors [6] 79 and found in the peripheral blood (PB) of patients with both non-metastatic (5-24%)
80
and metastatic (26-49%) disease [7, 8] Figure 1a) . At 228 apheresis, none of the subjects were receiving active treatment other than androgen 229 deprivation.
231
The apheresis workflow is depicted in Figure 1a . Each apheresis procedure lasted 232 between 90-160 minutes; apheresis product volume ranged from 40-100 mL 
267
Tumor biopsies (treatment-naïve diagnostic biopsies and/or metastatic biopsies) were 268 available for 12 of these 14 patients; these samples were also evaluated. Copy number 269 traces of single CTCs and matching, same patient, biopsies showed broadly similar 270 genomic profiles (Figure 1c, Supplementary Figure 3) , and again matched that of (Figures 3c and 3d) . 
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The apheresis from patient P05 also revealed heterogeneous CTCs; we successfully 
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Further work is also now needed to explore the clinical implications of this diversity in 
395
We acknowledge the limitations of the data presented, particularly with regards to the 396 limited cohort size and the fact that all the patients were treated at one tertiary cancer 
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